Graceptor®

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

the Maintenance Phase After Kidney Transplantation

Conditions

the Maintenance Phase After Kidney Transplantation

Trial Timeline

Nov 15, 2013 → Mar 31, 2016

About Graceptor®

Graceptor® is a pre-clinical stage product being developed by Astellas Pharma for the Maintenance Phase After Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT02160054. Target conditions include the Maintenance Phase After Kidney Transplantation.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT02160054Pre-clinicalCompleted

Competing Products

20 competing products in the Maintenance Phase After Kidney Transplantation

See all competitors
ProductCompanyStageHype Score
LY2422347 + placeboEli LillyPhase 2
52
LY2624803 - Solution + LY2624803 - Capsule + Placebo - Solution + Placebo - CapsuleEli LillyPhase 1
33
Zolpidem MR + EstazolamAstellas PharmaApproved
85
zolpidem MR + nitrazepam + placeboAstellas PharmaPhase 3
77
FK199B + ZolpidemAstellas PharmaPhase 3
77
ASP7991Astellas PharmaPhase 1
33
Zolpidem MR + Zolpidem IRAstellas PharmaApproved
85
Zolpidem MR + ZolpidemAstellas PharmaPhase 3
77
LemborexantEisaiPhase 2
52
Lemborexant + PlaceboEisaiPhase 3
77
LemborexantEisaiPre-clinical
23
Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved
85
Org 50081 + Org 50081 + Placebo + zopicloneMerckPhase 1
33
esmirtazapineMerckPhase 3
77
EsmirtazapineMerckPhase 3
77
Suvorexant + PlaceboMerckPhase 3
77
Esmirtazapine + PlaceboMerckPhase 3
77
Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetilNovartisApproved
85
Cyclosporine - cyclosporine microemulsionNovartisApproved
85
Enteric-coated Mycophenolate sodium (EC-MPS)NovartisApproved
85